| ¿µ¹® | hypersensitivity | ÇÑ±Û | °ú¹Î, ¿¹¹Î |
|---|---|---|---|
| ¼³¸í | 1. ¾î¶² ¾à¹°À̳ª Àڱؿ¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯ÈÇÑ »óÅÂ. °ú¹Î¼º ¹ÝÀÀÀº ¸é¿ª¹ÝÀÀ¿¡ ÀÇÇÏ¿© »ý±â´Â º´Àû °úÁ¤À¸·Î, Áï½ÃÇü¹ÝÀÀ°ú Áö¿¬Çü¹ÝÀÀÀ¸·Î ºÐ·ùµÈ´Ù. ¶ÇÇÑ ´ÙÀ½ÀÇ 4ÇüÀ¸·Î ºÐ·ùµÇ±âµµ ÇÑ´Ù. IÇüÀº Áï½ÃÇü °ú¹Î¼º ¹ÝÀÀ(¿¹ÄÁ´ë anaphylaxis). IIÇüÀº Á¶Á÷Ç׿ø¿¡ ´ëÇÑ Ç×ü¿¡ ÀÇÇÏ¿© »ý±â´Â ¼Õ»ó(¿¹ÄÁ´ë ÄáÆÏµ¶¼º ÄáÆÏ¿°). IIIÇüÀº Ç׿øÇ×üº¹ÇÕ¹°, ƯÈ÷ ¾à°£ÀÇ Ç׿øÀÇ °úÀ׿¡ ÀÇÇÏ¿© Çü¼ºµÇ´Â ¿ëÇØ¼º º¹ÇÕ¹°¿¡ ÀÇÇÏ¿© »ý±â´Â °Í(¿¹ÄÁ´ë ¾Æ¸£Åõ½º ¹ÝÀÀÀ̳ª Ç÷ûº´). IVÇüÀº Áö¿¬Çü °ú¹Ì¼º ¹ÝÀÀ(¿¹ÄÁ´ë Á¢Ã˼º ÇǺκ´)ÀÌ´Ù. 2. °¨°¢À̳ª °¨Á¤ÀÌ Áö³ªÄ¡°Ô ¿¹¹ÎÇÔ. |
||
| ¿µ¹® | immunological reaction | ÇÑ±Û | ¸é¿ª¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | »ýüÀÇ ¸ö ¾È¿¡¼ »ý±ä ¹°ÁúÀ̳ª ¸ö ¹Û¿¡¼ µé¾î¿Â ¹°ÁúÀÌ »ýü¿Í ´Ù¸¦ ¶§ ÀÚ±â ü³»ÀÇ ÅëÀϼº°ú °³Ã¼ÀÇ »ýÁ¸ À¯Áö ¹× Á¾ÀÇ Á¸¼ÓÀ» À§ÇÏ¿© ±× ¹°ÁúµéÀ» Á¦°ÅÇÏ´Â ÀÏ·ÃÀÇ »ýü ¹ÝÀÀ. ´Ù½Ã ¸»ÇØ B¼¼Æ÷¿¡ ÀÇÇÑ Ç×ü»ý»ê, T¼¼Æ÷¸¦ Áß½ÉÀ¸·Î ÇÏ´Â ¼¼Æ÷¼º ¸é¿ª, ¸é¿ª°ü¿ë, ¸é¿ª±â¾ï µîÀÇ »ýü ³» ¹ÝÀÀÀ» ¸»ÇÑ´Ù. Å«Æ÷½Ä¼¼Æ÷´Â Ç׿øÀ» ó¸®Çؼ ƯÀÌÀûÀÎ Ç׿ø°áÁ¤±â¸¦ °®´Â ºÐÀÚ·Î ¹Ù²ã, Ç׿ø°ú ÁÖ¿äÁ¶Á÷ ÀûÇÕÀ¯ÀüÀÚº¹ÇÕü¸¦ ¼¼Æ÷Ç¥¸é¿¡ Ç¥ÇöÇϸç, T¼¼Æ÷·Î Àü´ÞÇÑ´Ù. ÇÑÆí B¼¼Æ÷´Â Å«Æ÷½Ä¼¼Æ÷ ³»¿¡¼ ó¸®µÈ Ç׿øÀÇ °áÁ¤±â¸¦ ÀνÄÇÏ¿© ´ëÀÀÇϴ ƯÀÌÀûÇ×ü¸¦ »ý»êÇÏ¿© Ç׿øÀ» ó¸®ÇÑ´Ù. |
||
| ¿µ¹® | reaction formation | ÇÑ±Û | ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º |
|---|---|---|---|
| ¼³¸í | ¾ï¾Ðº¸´Ù ´õ Àû±ØÀûÀÎ ¹æ¾î¸ÞÄ¿´ÏÁòÀ̸ç, ¹«ÀǽÄÀûÀÎ »ý°¢, ¼Ò¿ø, Ãæµ¿ÀÌ ³Ê¹«³ªµµ ¹Þ¾Æµé¿©Áú ¼ö ¾ø´Â °ÍÀÏ °æ¿ì¿¡ À̿ʹ Á¤¹Ý´ë ¹æÇâÀÇ °ÍÀ» °Á¶ÇÔÀ¸·Î½á ±×·± ¹«ÀǽÄÀûÀÎ °ÍµéÀÌ ÀǽĵÇÁö ¾Ê°Ô ÇÏ´Â °úÁ¤. ¿¹¸¦ µé¸é °¡Àå °¡ÇÐÀûÀÎ ¼º°ÝÀÇ »ç¶÷ÀÌ »ýÃ¼ÇØºÎ ¹Ý´ë·ÐÀÚ°¡ µÇ´Â °æ¿ì¸¦ µé ¼ö ÀÖ´Ù. À̰ÍÀº ¶Ç °¡½¿ ±íÀÌ Àá°ÜÀÖ´Â µÎ·Á¿òÀÌ ÀǽĵǴ °ÍÀ» ÇÇÇϱâ À§Çؼ µÎ·Á¿òÀÇ ´ë»óÀÌ µÇ´Â Çൿ¿¡ °ñ¸ôÇÏ´Â °æ¿ìµµ Æ÷ÇÔÀÌ µÈ´Ù. ¿¹¸¦ µé¸é, ³²ÀÚ¿¡°Ô »óó¹ÞÁö ¾ÊÀ»±î ÇÏ´Â µÎ·Á¿ò¿¡ °¡µæ Âù ¼Ò³à°¡ ÀÌ °°Àº µÎ·Á¿òÀ» ºÎÁ¤ÇÏ·Á´Â ¼ö´ÜÀ¸·Î ³ÀâÇÑ ¼ºÇàÀ§¿¡ °ñ¸ôÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¶Ç ÀüóÀÇ Àڳฦ ¹Ì¿öÇÏ´Â °è¸ð°¡ ¿ÀÈ÷·Á Áö³ªÄ¥ Á¤µµ·Î ±× ¾ÆÀ̸¦ ±Í¿©¿öÇÏ´Â ÀÏ µûÀ§ÀÌ´Ù. |
||
| ¿µ¹® | complement fixation reaction | ÇÑ±Û | º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ ÀÖ¾î¼ º¸Ã¼¿Í °áÇÕÇÏ´Â Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇÏ´Â ¿ëÇ÷¼ÒÀÇ È¥ÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀÏ¾î³ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉÃ, Ŭ¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ. |
||
| ¿µ¹® | transfusion reaction | ÇÑ±Û | ¼öÇ÷ºÎÀÛ¿ë, ¼öÇ÷¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | ¼öÇ÷ÇÏ¿´À» ¶§¿¡ ȯÀÚ¿¡°Ô ÀϾ´Â ¹ÝÀÀ. ¾Ë·¹¸£±â ¹ÝÀÀ°ú ¿ëÇ÷ ¹ÝÀÀÀÌ ÀÖ´Ù. |
||
| LR | labeled release; laboratory references; laboratory report; labor room; lactated Ringer [solution]; l... |
|---|---|
| DHR | delayed hypersensitivity reaction; Department of Human Resources |
| DSHR | delayed skin hypersensitivity reaction |
| GHR | granulomatous hypersensitivity reaction |
| AAR | active avoidance reaction; acute articular rheumatism; antigen-antiglobulin reaction |
| DTH | Delayed type hypersensitivity reaction |
|---|---|
| CSH | Carotid sinus hypersensitivity |
| CH | Contact hypersensitivity |
| CHS | Contact hypersensitivity |
| CBH | Cutaneous basophil hypersensitivity |
| cytotoxic reaction | An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement. (05 Mar 2000) |
|---|---|
| hypersensitivity reaction | <immunology> The bodys response to an allergic stimulus. This can be localised to one area or generalised and may include: rash, itching, hives, swelling, difficulty breathing, and/or low blood pressure. (27 Sep 1997) |
| immediate hypersensitivity reaction | An immune response mediated by antibody, usually IgE, which occurs within minutes after a second encounter with an antigen, resulting in the release of histamine and subsequent swelling and vasodilation. (05 Mar 2000) |
| type III hypersensitivity reaction | An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis. See: autoimmune disease. Synonym: immune complex disorder, type III hypersensitivity reaction. (05 Mar 2000) |
| antireticular cytotoxic serum | An antiserum specific for cells of the reticuloendothelial system. (05 Mar 2000) |
| cytotoxic | <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration. (16 Dec 1997) |
| cytotoxic cell | Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells. Synonym: cytotoxic cell. (05 Mar 2000) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| cytotoxic T-cell | <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens). (18 Nov 1997) |
| cytotoxic t-lymphocyte | A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene: See: Ganciclovir. (09 Oct 1997) |
| cytotoxic T lymphocyte-specific serine protease | <enzyme> Structural sequence given in first source Registry number: EC 3.4.21.- Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II (26 Jun 1999) |
| T cytotoxic cells | Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors. (12 Dec 1998) |
| T-lymphocytes, cytotoxic | Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity. (12 Dec 1998) |
| vasculitis, hypersensitivity | Heterogeneous group of disorders characterised by a vasculitic syndrome presumed to be associated with a hypersensitivity reaction following exposure to an antigen such as an infectious agent, a drug, or other foreign or endogenous substance. (12 Dec 1998) |
| respiratory hypersensitivity | A form of hypersensitivity affecting the respiratory tract. It includes asthma and hay fever. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|